Email this article 
VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
- Authors: Byalik T.E.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 13, No 2 (2018)
- Pages: 32-38
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 13.07.2018
- URL: https://oncohematology.abvpress.ru/ongm/article/view/286
- DOI: https://doi.org/10.17650/1818-8346-2018-13-2-32-38
- ID: 286
Cite item
Full Text
Abstract
In recent years, great progress has been made in understanding biology and pathogenesis of chronic lymphocytic leukemia. The key thing in disease pathogenesis is the apoptosis resistance of tumor cells. One of the main regulators of programmed cell death is the Bcl-2 family proteins. Important role of Bcl-2 protein in carcinogenesis made it an attractive target for therapeutic intervention. This review focuses on venetoclax (a selective inhibitor of the anti-apoptotic Bcl-2 protein) in the treatment of chronic lymphocytic leukemia.
Keywords
About the authors
T. E. Byalik
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: bialik@bk.ru
23 Kashirskoye Shosse, Moscow 115478 Russian Federation
References
Supplementary files
